UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
November 14, 2022
ALLIED HEALTHCARE PRODUCTS, INC.
(Exact name of Company as specified in its charter)
| Delaware | 0-19266 | 25-1370721 |
(State or Other Jurisdiction
of Incorporation) | (Commission
File Number) | (IRS Employer
Identification No.) |
1720 Sublette Avenue, St. Louis, Missouri
(Address of principal executive offices) | 63110
(Zip Code) |
| Company’s telephone number, including area code |
| (314) 771-2400 |
| |
| Not applicable |
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the Company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging Growth Company ¨
If an emerging growth company, indicate by check mark if the Company has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of Each Exchange on Which
Registered |
| Common Stock, $.01 | AHPI | The NASDAQ Stock Market, LLC |
Item 2.02 Results of Operations and Financial Condition.
On November 14, 2022 Allied Healthcare Products, Inc. (the “Company” or “Allied”) filed Form 12b-25 Notification of Inability to Timely File its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022. In the form 12b-25, Allied disclosed the following information regarding the results of operations and financial condition of the Company:
The Company expects to report a loss of $1.6 million before taxes for the quarter, compared to a loss of $1.0 million before taxes for the same period of fiscal year 2022.
Net sales for the quarter of $5.2 million are expected to be $2.2 million or 29.7% lower than the comparable quarter in fiscal 2022. Domestically, sales decreased by $1.9 million dollars while international sales, which represented 22.5% of the quarter’s sales, were $0.3 million lower. Sales for the quarter continued to be negatively impacted by delays in obtaining inputs, production delays, and a staffing shortage in our manufacturing operation.
The Company also expects to report that during the quarter it used $2.1 of cash in operating activities.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | ALLIED HEALTHCARE PRODUCTS, INC. |
| | | |
| | By: | |
| | | |
| Date: November 15, 2022 | | /s/ Daniel C. Dunn |
| | | Daniel C. Dunn |
| | | Chief Financial Officer |
